{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:04:59Z","timestamp":1794449099959,"version":"4.9.1"},"reference-count":47,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018710","name":"NCCR AntiResist","doi-asserted-by":"crossref","award":["180541"],"award-info":[{"award-number":["180541"]}],"id":[{"id":"10.13039\/100018710","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["32003B_204944"],"award-info":[{"award-number":["32003B_204944"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["221668"],"award-info":[{"award-number":["221668"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,3,27]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (\n                      <jats:italic>S. aureus<\/jats:italic>\n                      ) bacteraemia is a common and severe infection. With mortality rates ranging from 20\u201330%\u2009and long-term impairments in over a third of survivors, better treatments are urgently needed. Linezolid, a well-established treatment for pneumonia and complicated skin infections, has been shown in preclinical studies to strongly suppress\n                      <jats:italic>S. aureus<\/jats:italic>\n                      virulence factors critical to bacterial persistence and tissue damage. Hence, we aim to investigate whether the addition of linezolid to standard therapy in patients with\n                      <jats:italic>S. aureus<\/jats:italic>\n                      bacteraemia leads to an overall improvement in patient-relevant outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      We will conduct a two-arm, parallel-group, multicentre, randomised controlled trial (Linezolid Plus Standard of Care) in 12 hospitals in Switzerland with blinded treating physicians, patients and outcome assessors. Hospitalised patients aged \u226518 years with\n                      <jats:italic>S. aureus<\/jats:italic>\n                      bacteraemia will be eligible. Patients will receive standard antibiotic treatment as prescribed by the treating physician. Within 72 hours of collection of the blood sample yielding the first positive blood culture, patients will be enrolled and randomised 1:1 to receive either adjunctive linezolid (600\u2009mg orally two times per day for 5\u2009days) or placebo. To determine patient-relevant outcomes, we implemented a comprehensive patient-representative consultation process. Consequently, we will use the desirability of outcome ranking (DOOR) established for\n                      <jats:italic>S. aureus<\/jats:italic>\n                      bacteraemia as the primary outcome at 90 days. The hierarchical composite DOOR outcome includes the following four components, ranked from most to least important: (1) survival, (2) return to level of function before\n                      <jats:italic>S. aureus<\/jats:italic>\n                      infection, (3) complications leading to treatment changes and serious adverse reactions; and (4) hospital length of stay. This approach will allow us to analyse the win ratio, that is, whether patients receiving linezolid have a better DOOR rank compared to patients in the placebo group. We calculated a target sample size of 606 patients providing 90% power at a two-sided significance level of 0.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was received from the Ethics committee for Northern and Central Switzerland (BASEC number 2025-00655). Eligible patients will be informed about the study by the local study team and asked for written consent if they wish to participate. For patients unable to provide informed consent, an appropriate substitute (ie, a close relative or a physician not involved in the research project) may make decisions based on the presumed wishes and the best interest of the patient. The patient\u2019s own consent will be obtained as soon as their condition permits. Results will be published in peer-reviewed journals and in laymen's terms through various channels (social media, Swiss national portal HumRes).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06958835\">NCT06958835<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-118509","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:45:56Z","timestamp":1776696356000},"page":"e118509","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Linezolid in addition to standard antibiotic treatment for\n                    <i>Staphylococcus aureus<\/i>\n                    bacteraemia: study protocol for a randomised, placebo-controlled trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06958835","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06958835","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06958835","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06958835","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5102-4385","authenticated-orcid":false,"given":"Natalie","family":"Rose","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland"},{"name":"Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine S","family":"Bernasconi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Schumacher","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Werlen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"B\u00fcchel","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Weisser","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin B","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"},{"name":"Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4769-636X","authenticated-orcid":false,"given":"Elisabeth","family":"Wehrle-Wieland","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Claraspital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Conen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Infection Prevention, Cantonal Hospital Aarau, Aarau, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Thurnheer","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Inselspital and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital Inselspital and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Birrer","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine \/ Infectious Diseases, H\u00f4pital du Jura, Del\u00e9mont, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2999-3707","authenticated-orcid":false,"given":"Marco","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner C","family":"Albrich","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Infection Prevention and Travel Medicine, HOCH Health Ostschweiz, Cantonal Hospital St. Gallen, St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Karrer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Cantonal Hospital Winterthur, Winterthur, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5170-0254","authenticated-orcid":false,"given":"Adrian","family":"Schibli","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Infection Prevention, Stadtspital Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Harbarth","sequence":"additional","affiliation":[{"name":"Infection Control Program and World Health Organization Collaborating Centre, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthaios","family":"Papadimitriou-Olivgeris","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-5230","authenticated-orcid":false,"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[{"name":"CLEAR-Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Hasse","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University Hospital and University of Zurich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kuehl","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3301-8085","authenticated-orcid":false,"given":"Benjamin","family":"Speich","sequence":"additional","affiliation":[{"name":"CLEAR-Methods Center, Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"2026042007451860000_16.4.e118509.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)02185-7"},{"key":"2026042007451860000_16.4.e118509.2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s15010-023-01980-6","article-title":"Increase in methicillin-susceptible Staphylococcus aureus bloodstream infections in Switzerland: a nationwide surveillance study (2008-2021)","volume":"51","author":"Renggli","year":"2023","journal-title":"Infection"},{"key":"2026042007451860000_16.4.e118509.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03903.x"},{"key":"2026042007451860000_16.4.e118509.4","article-title":"Incidence Trends and Epidemiology of Staphylococcus aureus Bacteremia: A Systematic Review of Population-Based Studies","volume":"14","author":"Hindy","year":"2022","journal-title":"Cureus"},{"key":"2026042007451860000_16.4.e118509.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01589.x"},{"key":"2026042007451860000_16.4.e118509.6","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.cmi.2023.05.031","article-title":"Increasing numbers and complexity of Staphylococcus aureus bloodstream infection-14 years of prospective evaluation at a German tertiary care centre with multi-centre validation of findings","volume":"29","author":"Math\u00e9","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026042007451860000_16.4.e118509.7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ijid.2022.06.026","article-title":"Staphylococcus aureus bacteremia mortality across country income groups: A secondary analysis of a systematic review","volume":"122","author":"Bai","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026042007451860000_16.4.e118509.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.10.015"},{"key":"2026042007451860000_16.4.e118509.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.03.015"},{"key":"2026042007451860000_16.4.e118509.10","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2017.14508","article-title":"Survival from methicillin-sensitive Staphylococcus aureus bloodstream infections over 20 years: a cohort of 1328 patients","volume":"147","author":"Wiggli","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"2026042007451860000_16.4.e118509.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300220"},{"key":"2026042007451860000_16.4.e118509.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30447-3"},{"key":"2026042007451860000_16.4.e118509.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz112"},{"key":"2026042007451860000_16.4.e118509.14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/cid\/ciab742","article-title":"Microbial Cell-Free DNA Identifies Etiology of Bloodstream Infections, Persists Longer Than Conventional Blood Cultures, and Its Duration of Detection Is Associated With Metastatic Infection in Patients With Staphylococcus aureus and Gram-Negative Bacteremia","volume":"74","author":"Eichenberger","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026042007451860000_16.4.e118509.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-008-0515-5"},{"key":"2026042007451860000_16.4.e118509.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2015.09.037"},{"key":"2026042007451860000_16.4.e118509.17","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/cid\/ciab201","article-title":"Comparable Outcomes of Short-Course and Prolonged-Course Therapy in Selected Cases of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Pooled Cohort Study","volume":"73","author":"Thorlacius-Ussing","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026042007451860000_16.4.e118509.18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0103"},{"key":"2026042007451860000_16.4.e118509.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2020.02.005"},{"key":"2026042007451860000_16.4.e118509.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00852-y"},{"key":"2026042007451860000_16.4.e118509.21","doi-asserted-by":"crossref","DOI":"10.3390\/toxins13100677","article-title":"Staphylococcus aureus Toxins: An Update on Their Pathogenic Properties and Potential Treatments","volume":"13","author":"Ahmad-Mansour","year":"2021","journal-title":"Toxins (Basel)"},{"key":"2026042007451860000_16.4.e118509.22","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10111396","article-title":"Contribution of Coagulase and Its Regulator SaeRS to Lethality of CA-MRSA 923 Bacteremia","volume":"10","author":"Liu","year":"2021","journal-title":"Pathogens"},{"key":"2026042007451860000_16.4.e118509.23","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac653","article-title":"All-Cause and Infection-Related Mortality in Staphylococcus aureus Bacteremia, a Multicenter Prospective Cohort Study","volume":"9","author":"van der Vaart","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026042007451860000_16.4.e118509.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03540370048035"},{"key":"2026042007451860000_16.4.e118509.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201812-2383CP"},{"key":"2026042007451860000_16.4.e118509.26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cid\/ciaa611","article-title":"Patients\u2019 Experiences With Staphylococcus aureus and Gram-negative Bacterial Bloodstream Infections: A Qualitative Descriptive Study and Concept Elicitation Phase To Inform Measurement of Patient-reported Quality of Life","volume":"73","author":"King","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026042007451860000_16.4.e118509.27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.4288"},{"key":"2026042007451860000_16.4.e118509.28","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00120-16"},{"key":"2026042007451860000_16.4.e118509.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3452-y","article-title":"CASSETTE-clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation: study protocol for a randomised controlled trial","volume":"20","author":"Dotel","year":"2019","journal-title":"Trials"},{"key":"2026042007451860000_16.4.e118509.30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu444"},{"key":"2026042007451860000_16.4.e118509.31","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"2026042007451860000_16.4.e118509.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.05.003"},{"key":"2026042007451860000_16.4.e118509.33","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa114","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"3","author":"Brown","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026042007451860000_16.4.e118509.34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy774"},{"key":"2026042007451860000_16.4.e118509.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.05.003"},{"key":"2026042007451860000_16.4.e118509.36","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac476"},{"key":"2026042007451860000_16.4.e118509.37","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-023-07718-x","article-title":"A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial","volume":"24","author":"Mahar","year":"2023","journal-title":"Trials"},{"key":"2026042007451860000_16.4.e118509.38","unstructured":"Swissethics . Interpretationshilfe f\u00fcr Forschung in Notfallsituationen, Available: https:\/\/swissethics.ch\/templates\/forschung-in-notfallsituationen"},{"key":"2026042007451860000_16.4.e118509.39","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/cid\/ciy766","article-title":"Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection","volume":"68","author":"Doernberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026042007451860000_16.4.e118509.40","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2016.1207561"},{"key":"2026042007451860000_16.4.e118509.41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cmi.2019.10.011","article-title":"Measuring patient-centred long-term outcome following a bloodstream infection: a pilot study","volume":"26","author":"McNamara","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026042007451860000_16.4.e118509.42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr352"},{"key":"2026042007451860000_16.4.e118509.43","unstructured":"Open Science Framework . Study protocol: Randomized trials using a hierarchical composite primary endpoint: a systematic scoping review, Available: https:\/\/osf.io\/mjc52"},{"key":"2026042007451860000_16.4.e118509.44","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1093\/cid\/ciaf314","article-title":"Making Sense of Hierarchical Composite End Points in Randomized Clinical Trials-A Primer for Infectious Diseases Clinicians and Researchers","volume":"81","author":"Ong","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026042007451860000_16.4.e118509.45","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.130430"},{"key":"2026042007451860000_16.4.e118509.46","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00420-1"},{"key":"2026042007451860000_16.4.e118509.47","doi-asserted-by":"crossref","DOI":"10.1186\/s13741-025-00550-8","article-title":"Efficient statistical analysis of trial designs: win ratio and related approaches for composite outcomes","volume":"14","author":"Fandino","year":"2025","journal-title":"Perioper Med (Lond)"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-118509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:46:03Z","timestamp":1776696363000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-118509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,20]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjopen-2026-118509"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118509","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118509.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118509.supp2","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118509.supp3","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118509.supp4","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2026-118509.supp5","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}